Journal article
Prevalence and clinical correlates of bronchoreversibility in severe emphysema
The European respiratory journal, Vol.35(5), pp.1048-1056
05/01/2010
DOI: 10.1183/09031936.00052509
PMID: 19926748
Abstract
Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is not fully reversible. The importance of bronchoreversibility remains controversial.
We hypothesised that an emphysematous phenotype of COPD would be associated with decreased bronchoreversibility.
544 patients randomised to the medical arm of the National Emphysema Treatment Trial formed the study group. Participants underwent multiple measurements of bronchoreversibility on a mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms, quality of life and quantitative measures of emphysema by computed tomography.
Mean baseline forced expiratory volume in 1 s (FEV1) in this patient population is 24% predicted. 22.2% of patients demonstrated bronchoreversibility on one or more occasions using American Thoracic Society/European Respiratory Society criteria. Few patients (0.37%) had bronchoreversibility on all completed tests. Patients who demonstrated bronchoreversibility were more likely to be male, and have better lung function and less emphysema. 64% of patients demonstrated large (>= 400 mL) changes in forced vital capacity (FVC).
In a severe emphysema population, bronchoreversibility as defined by change in FEV1 is infrequent, varies over time, and is more common in males and those with less severe emphysema. Improvements in FVC, however, were demonstrated in the majority of patients.
Details
- Title: Subtitle
- Prevalence and clinical correlates of bronchoreversibility in severe emphysema
- Creators
- M. K. Han - University of Michigan–Ann ArborR. Wise - Johns Hopkins UniversityJ. Mumford - University of California, Los AngelesF. Sciurba - University of PittsburghG. J. Criner - Temple UniversityJ. L. Curtis - University of Michigan–Ann ArborS. Murraye - Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USAA. Sternberg - Johns Hopkins UniversityG. Weinman - National Institutes of HealthE. Kazerooni - University of Michigan–Ann ArborA. P. Fishman - University of PennsylvaniaB. Make - University of DenverE. A. Hoffman - University of IowaZ. Mosenifar - Cedars-Sinai Medical CenterF. J. Martinez - University of Michigan–Ann ArborNational Emphysema Treatment Trial (NETT) Research Group
- Resource Type
- Journal article
- Publication Details
- The European respiratory journal, Vol.35(5), pp.1048-1056
- DOI
- 10.1183/09031936.00052509
- PMID
- 19926748
- NLM abbreviation
- Eur Respir J
- ISSN
- 0903-1936
- eISSN
- 1399-3003
- Publisher
- European Respiratory Soc Journals Ltd
- Number of pages
- 9
- Grant note
- N01HR76101; N01HR76102; N01HR76103; N01HR76104; N01HR76105; N01HR76106; N01HR76107; N01HR76108; N01HR76109; N01HR76110; N01HR76111; N01HR76112; N01HR76113; N01HR76114; N01HR76115; N01HR76116; N01HR76118; N01HR76119 / National Heart, Lung, and Blood Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) N01HR076112 / DIVISION OF LUNG DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) K23HL068713 / NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)
- Language
- English
- Date published
- 05/01/2010
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Radiology; Internal Medicine
- Record Identifier
- 9984318699802771
Metrics
4 Record Views